Clinical Trial Update: Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia [Phase 1]

View source ↗

Summary

The document provides a clinical trial update for a Phase 1 study of YTS109 cell in recurrent/refractory autoimmune hemolytic anemia, with the trial currently n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• YTS109 cell (YTS109)

Snippet

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. | Conditions: Autoimmune Hemolytic Anemia | Phase 1 | Status: NOT_YET_RECRUITING